Relaxation of superflow in a network: an application to the dislocation model of supersolidity of helium crystals

We have considered the dislocation network model for the supersolid state in He-4 crystals. In difference with uniform 2D and 3D systems, the temperature of superfluid transition T_c in the network is much smaller than the degeneracy temperature T_d. It is shown that a crossover into a quasi superfluid state occurs in the temperature interval between T_c and T_d. Below the crossover temperature the time of decay of the flow increases exponentially under decrease of the temperature. The crossover has a continuous character and the crossover temperature does not depend on the density of dislocations.Comment: Corrected typo

Intermittent intravenous ibandronate therapy for osteoporosis

The author consecutively considers the introduction of intermittent use of ibandronate (I), by determining its single dose and annual cumulative dose. She presents data on the adequate antiresorptive activity of intermittent treatment, shows it necessary to design an intravenous dosage form of the drug and gives detailed data on the efficacy of parenteral I. The fact that the agent may be used in secondary (steroidal) osteoporosis is provided. There is evidence that the risk of extravertebral and all clinical fractures reduces when I is intravenously injected in a dose of 3 mg quarterly and orally administered in a dose of 150 mg monthly

RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS

The present review is devoted to the risk factors of osteoporosis progression in patients with rheumatoid arthritis (RA), both relevant and irrelevant to the main disease. It is assumed that the most important predictors of the bone mineral density decrease is severe course of RA, significant functional disability (according to HAQ), glucocorticoid therapy, elderly age, low body mass index and menopause. However, despite the vast amount of studies, results on the risk factors of osteoporosis remain ambiguous and require further investigation

Analgesic treatment, by using a systemic algorithm

To control musculoskeletal pain (MSP) is an important component of combination treatment for systemic inflammatory rheumatic diseases, such as rheumatoid arthritis and spondyloarthritis, and a major area of therapy for osteoarthritis and nonspecific back pain. Pain development is associated with a number of pathogenetic mechanisms: local involvement; involvement of the elements of the ligamentous apparatus; chronic muscle tension; biomechanical disorders; dysfunction of the nociceptive system. This necessitates a comprehensive approach during analgesic therapy, with combined use of drugs having a different mechanism of analgesic action. This review considers the targets of pharmacotherapy for MSP and the main groups of medications that may affect them. The paper proposes an analgesic treatment algorithm based on the diagnosis of individual elements of the pathogenesis of chronic MSP and on the successive assessment of treatment results

Интермиттирующая терапия остеопороза с помощью внутривенной формыибандроната

The author consecutively considers the introduction of intermittent use of ibandronate (I), by determining its single dose and annual cumulative dose. She presents data on the adequate antiresorptive activity of intermittent treatment, shows it necessary to design an intravenous dosage form of the drug and gives detailed data on the efficacy of parenteral I. The fact that the agent may be used in secondary (steroidal) osteoporosis is provided. There is evidence that the risk of extravertebral and all clinical fractures reduces when I is intravenously injected in a dose of 3 mg quarterly and orally administered in a dose of 150 mg monthly.Последовательно рассмотрено внедрение интермиттирующего назначения ибандроната (И) с определением его однократной дозы и годовой кумулятивной дозы. Приведены данные о достаточной антирезорбтивной активности прерывистого курса лечения. Показана необходимость создания внутривенной формы препарата и подробно представлены данные об эффективности парентерального И, освещена возможность его применения при вторичном (стероидном) остеопорозе. Приведены доказательства уменьшения риска внепо-звоночньа и всех клинических переломов при внутривенном введении 3 мг И ежеквартально и пероральном приеме 150 мг ежемесячно

Association of the rs2167270 polymorphism of the leptin gene (LEP) with the intensity of pain in patients with osteoarthritis of the knee

Background: Osteoarthritis (OA) is a significant social problem as it is the most common disease of the joints. OA is a multifactorial disease in which great attention is paid to hereditary factors. Recently, a number of studies have demonstrated the contribution of a number of genes to the subjective assessment of pain in OA, which is the main symptom of this disease. The association of P2X7, TRPV1 and TACR1 genes and some others with pain sensitivity has been shown. One of the risk factors of pain among many others, is the increased weight. Abdominal adipose tissue is a source of release of pro-inflammatory adipokines that cause systemic inflammation associated with damage to many tissues, including subchondral bone, synovial membrane. Leptin is an endogenous hormone from the adipokine family encoded by the obesity gene leptin (LEP) and which is synthesized primarily in adipocytes.Aims: To investigate the possible association of rs2167270 (A19G) polymorphism of the LEP gene with pain intensity in ­patients with knee OA.Materials and methods: The study was conducted among women diagnosed with OA. Using the VAS scale (Visual analog scale), patients with mild knee pain — group 1 (VAS ≤ 40 mm) and patients with moderate or severe pain — group 2 (VAS>40 mm) were selected for pain assessment. Genetic variants of A19G leptin gene polymorphism were studied by polymerase chain reaction followed by restriction fragment length analysis (PCR-RFLP) method.Results: In the group of patients with moderate or severe pain intensity (group 2, n=61), a statistically significant association was shown with a higher body mass index (p=0.006) and an increased frequency of carriers of the 19GG genotype (p=0,051) compared to group 1 (n=36). Carriers of the 19GG genotype statistically significantly had a higher rate of knee pain and an early age of OA debut compared to carriers of the 19AA genotype (p=0,035 and p=0,015, respectively).Conclusions: The findings open up new possibilities for predicting pain symptoms in patients with knee OA by genetic testing of A19G polymorphic variants of the leptin gene

Influence of organic solvents and surfactants on photoactivation process of dielectric materials

For the photoselective activation of the surface of inorganic dielectric materials and fiberglass with an epoxy-rubber adhesive layer, compositions based on copper(II) compounds containing sodium salts of anthraquinon sulfonic acids and secondary sorbitol and ethanol as an optical sensitizer can be used. The metallization process of dielectric materials, in particular, copper plating is autocatalytic. The catalyst is the surface of an already formed copper coating. The concentration of catalytically active centers on the surface of the dielectric should be high enough to produce the high-quality solid copper coating. Organic solvents (dimethylformamide and dimethylsulfoxide) are entered a photosensitive composition for an increase in the amount of copper(II) at the surfaces of the dielectric. They are used at a stage of swelling of an epoxyrubber adhesive layer of fiber glasses by preparation of a dielectric surface. In this case, the photosensitive composition is fixed on the surface of the dielectric not only due to microroughness but also is capable to get deep into the bulked-up adhesive layer. The amount of copper(II) deposited on the surface of the dielectric in the composition of the photocomposition was determined using atomic absorption (AAMA) and X-ray diffraction fluorescence analysis methods (RSFA). It is established that the amount of copper(II) on the surface of the dielectric increases by 2a3 times at increase in time of drawing photocomposition from 0.5 to 5 of minutes. Thus, the photosensitive layer is fixed on the dielectric surface not only due to microroughness but also due to the adsorption of photocomposition by an adhesive layer. It is shown that the amount of copper(II) on a surface is more than when drawing photocomposition with dimethylformamide when drawing on the dielectric of the photocomposition containing 10% volume a dimethylsulfoxide. This suggests that the swelling of the adhesive layer in DMSO is more effective. It is established that the introduction of organic solvents into the photoactivator composition increases the concentration of copper(II) on the surface and in the adhesive layer. For the best fixing of photocomposition on the surface of the dielectric material, the photoactivator was entered into the structure of the photoactivator. Introduction to the structure of the photoactivator of surfactants increases the speed of photorestoration of copper(II) in a dry layer of the photoactivator. Surfactants increase the amount of copper(II) by the surfaces of the dielectric and promote the best distribution of the photoactivator. Nonionic surfactant of the OP-10 brand as a part of the photoactivator considerably increases adhesion of a metal coating to the dielectric. © 2019 Author(s)